ArticleJournal of neuro-oncology2025
Predictive markers for molecular subtypes and WHO grade: T1ρ-MRI in adult-type diffuse gliomas.
Article in Journal of neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- TNMR in biomedicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundThis study aimed to investigate the utility of quantitative T1ρ magnetic resonance imaging (T1ρ-MRI) in predicting the WHO grade, isocitrate dehydrogenase (IDH) mutation, and O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation in adult-type diffuse gliomas, and compare their performance across different spin-lock frequencies (FSLs).
methodsA total of 62 patients were prospectively recruited and underwent preoperative imaging, including morphological MRI (mMRI), diffusion-weighted imaging (DWI) and T1ρ-MRI. T1ρ was performed with FSLs set at 100 Hz, 200 Hz, and 500 Hz. Group comparisons by IDH mutation, WHO grade, and MGMT status were performed using t-tests and chi-square tests. Logistic regression analysis was employed to identify features independently. Receiver operating characteristic (ROC) curve analysis was performed to evaluate the diagnostic performance of the predictive models.
resultsThe apparent diffusion coefficient (ADC) and T1ρ values were significantly lower in patients with high-grade gliomas (HGGs) and IDH wildtype tumors compared to the control group (p < 0.05). T1ρ (FSL = 500 Hz) was identified as an independent predictor of IDH mutation status (p < 0.05) and demonstrated the highest diagnostic performance for predicting IDH mutation (AUC = 0.873; 95% CI: 0.782-0.951; p < 0.001). The combination of mMRI and ADC outperformed individual parameters. When T1ρ was added to the mMRI + ADC model, the resulting mMRI + ADC + T1ρ model achieved higher AUC values for both WHO grade and IDH mutation than the mMRI + ADC model alone, but these differences were not statistically significant (0.948 vs. 0.933, p = 0.205; 0.920 vs. 0.866, p = 0.150, respectively).
conclusionT1ρ-MRI demonstrates promising clinical value in predicting WHO grade and IDH mutation in gliomas. Notably, T1ρ at 500 Hz showed superior diagnostic performance compared to ADC and lower FSL settings. Integrating mMRI and ADC further enhances diagnostic accuracy, whereas adding T1ρ-MRI provides no significant additional benefit despite a slight numerical gain.
Indexed as
Identifiers
41085784What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.